نتایج جستجو برای: mf59

تعداد نتایج: 256  

2013
Giedre Gefenaite Margot Tacken Jens Bos Irina Stirbu-Wagner Joke C. Korevaar Ronald P. Stolk Bert Wolters Marc Bijl Maarten J. Postma Jan Wilschut Kristin L. Nichol Eelko Hak

INTRODUCTION Because of variability in published A(H1N1)pdm09 influenza vaccine effectiveness estimates, we conducted a study in the adults belonging to the risk groups to assess the A(H1N1)pdm09 MF59-adjuvanted influenza vaccine effectiveness. METHODS VE against influenza and/or pneumonia was assessed in the cohort study (n>25000), and vaccine effectiveness against laboratory-confirmed A(H1N...

Journal: :Vaccine 2011
Luis A Brito Michelle Chan Barbara Baudner Simona Gallorini George Santos Derek T O'Hagan Manmohan Singh

Emulsions have been used to boost immunogenicity of antigens since the discovery of complete Freunds adjuvant. Optimization to reduce reactogenicity of emulsion adjuvants lead to the development of oil in water emulsions based on squalene. MF59 is an oil-in-water emulsion that is a component of an approved influenza product in Europe. Currently MF59 is manufactured from squalene derived from an...

Journal: :Vaccine 2014
Sharon E Frey Mari Rose Aplasca-De Los Reyes Humberto Reynales Nancy Nazaire Bermal Uwe Nicolay Vas Narasimhan Eduardo Forleo-Neto Ashwani Kumar Arora

AIM Adjuvanted influenza vaccines can overcome the poor antibody response of conventional non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity, safety and clinical effectiveness of an MF59(®)-adjuvanted trivalent influenza vaccine (aTIV) compared with a non-adjuvanted vaccine (TIV) in subjects ≥65 years old, with or without co-morbidities. METHODS In 2010-2011, subjects (N=...

Journal: :The Journal of infectious diseases 2015
Sook-San Wong Bryan Kaplan Mark Zanin Jennifer Debeauchamp Lisa Kercher Jeri-Carol Crumpton Patrick Seiler Yilun Sun Li Tang Scott Krauss Robert Webster Richard J Webby

BACKGROUND An effective vaccine is urgently needed against the H7N9 avian influenza virus. We evaluated the immunogenicity and protective efficacy of a split-virion H7N9 vaccine with or without the oil-in-water adjuvants in ferrets. METHODS Ferrets were vaccinated with 2 doses of unadjuvanted, MF59 or AS03-adjuvanted A/Shanghai/2/2013 (H7N9) vaccine, and the induction of antibodies to hemaggl...

Journal: :Journal of virology 2005
Wing-pui Kong Ling Xu Konrad Stadler Jeffrey B Ulmer Sergio Abrignani Rino Rappuoli Gary J Nabel

Although the initial isolates of the severe acute respiratory syndrome (SARS) coronavirus (CoV) are sensitive to neutralization by antibodies through their spike (S) glycoprotein, variants of S have since been identified that are resistant to such inhibition. Optimal vaccine strategies would therefore make use of additional determinants of immune recognition, either through cellular or expanded...

2015
Nicos Karasavvas Chitraporn Karnasuta Hathairat Savadsuk Sirinan Madnote Dutsadee Inthawong Somsak Chantakulkij Surawach Rittiroongrad Sorachai Nitayaphan Punnee Pitisuttithum Prasert Thongcharoen Vinai Siriyanon Charla A. Andrews Susan W. Barnett James Tartaglia Faruk Sinangil Donald P. Francis Merlin L. Robb Nelson L. Michael Viseth Ngauy Mark S. de Souza Robert M. Paris Jean-Louis Excler Jerome H. Kim Robert J. O'Connell

RV144 correlates of risk analysis showed that IgG antibodies to gp70V1V2 scaffolds inversely correlated with risk of HIV acquisition. We investigated IgG antibody responses in RV135 and RV132, two ALVAC-HIV prime-boost vaccine trials conducted in Thailand prior to RV144. Both trials used ALVAC-HIV (vCP1521) at 0, 1, 3, and 6 months and HIV-1 gp120MNgD and gp120A244gD in alum (RV135) or gp120SF2...

2013
F Rubinstein P Micone A Bonotti V Wainer A Schwarcz F Augustovski A Pichon Riviere A Karolinski

OBJECTIVE To assess the risk of adverse perinatal events of vaccination of pregnant women with an MF59 adjuvanted vaccine. DESIGN Cross sectional multicentre study. SETTING 49 public hospitals in major cities in Argentina, from September 2010 to May 2011. PARTICIPANTS 30,448 mothers (7293 vaccinated) and their 30,769 newborns. MAIN OUTCOME MEASURE Primary composite outcome of low birth ...

Journal: :Vaccine 2012
Humberto Reynales Pedro Astudillo Serge de Vallière Christoph Hatz Patricia Schlagenhauf Barbara Rath Priscilla Velentgas Ariel Fariña Victor Sales-Carmona Nicola Groth

BACKGROUND The present study was a prospective observational study to evaluate the safety profile of Celtura(®), a monovalent, cell culture-derived, inactivated subunit influenza vaccine prepared from A/California/07/2009(H1N1) with the adjuvant MF59(®). Subjects were enrolled prospectively during the H1N1 2009 influenza pandemic at medical centres in Colombia, Chile, Switzerland, and Germany d...

Journal: :Japanese journal of infectious diseases 2012
Se-Min Hwang Hack-Lyoung Kim Kyueng-Whan Min Min Kim Jae-Sung Lim Jin-Man Choi Byung-Chul Chun Min-Jeong Kim Sang-Min Lee Seung-Young Kim Han-Ho Jeon

The first large-scale outbreaks of respiratory disease in the 21st century were caused by the influenza A (H1N1) virus in 2009, which affected mostly young adults. The M59 vaccine was developed to control pandemic influenza A (H1N1). However, the complications arising from the use of the non-adjuvanted and adjuvanted vaccines in young male Korean soldiers have not previously been evaluated ...

2017
Munir M. Mosaheb Michael L. Reiser Lee M. Wetzler

Vaccines are critical in the fight against infectious diseases, and immune-stimulating adjuvants are essential for enhancing vaccine efficacy. However, the precise mechanisms of action of most adjuvants are unknown. There is an urgent need for customized and adjuvant formulated vaccines against immune evading pathogens that remain a risk today. Understanding the specific role of various cell ty...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید